Lifeboat Foundation

The hNSCs used in the study have been produced and characterised in the Cell Factory and Biobank of Santa Maria Hospital (Terni, Italy), authorised by the Italian Medicine Agency (AIFA) for the production of hNSCs to be used for clinical trials (aM 54/2018). The methodology applied to isolate, expand, characterise and cryopreserve the lines is based on the Neurosphere Assay^26,41,54, and has been used for the production of the cells utilised in phase I trials for Amyotrophic Lateral Sclerosis patients (NCT01640067²³) and for Secondary Progressive Multiple Sclerosis patients (NCT03282760, ongoing).

The entire production process, starting from tissue procurement to cryopreservation is compliant to cGMP guidelines and approved by AIFA. The hNSCs are obtained from foetal brain tissue derived from fetuses that underwent miscarriage or natural in utero death upon receiving the signed informed consent from the mother. Forty-eight hours prior to implantation, hNSCs were plated in the growth medium at a concentration of 10,000 cells/cm². On the day of surgery, hNSCs were collected by centrifugation, viable cells were counted by Trypan blue exclusion criteria, and the correct number of cells were re-suspended in HBSS for the transplant.

SOD1 transgenic male rats were randomly divided into three experimental groups: (i) transplanted with hNSCs (hNSC rats, n = 15); (ii) treated with HBSS (HBSS rats, n = 15) and (iii) untreated (CTRL rats, n = 22). An additional group of non-transgenic littermates (wild-type, WT, n = 9) were used as controls for symptomatic evaluation of the colony. Tacrolimus (FK506) and cyclosporine (cyclosporin A) are the principal immunosuppressive drugs that have been applied for solid organ transplantation^55,56 and have been translated to stem cell treatments for PD⁵⁷ and ALS²². In animal models, despite differences in potency, both drugs showed excellent survival rates for grafts across many comparative studies^58,59. Our previous results^44,45 showed that hNSCs can survive—without signs of rejection—in the rat brain up to 6 months under transient immunosuppression treatment, with cyclosporin A. On the bases of these results, we applied the same immunosuppressive treatment with administration of cyclosporine A (15 mg/kg/day subcutaneous; Sandimmne, Novartis) that was initiated on the day of transplantation and continued for 15 days after surgery (for all animal groups).

What if death was not the end? What if, instead of saying our final goodbyes to loved ones, we could freeze their bodies and bring them back to life once medical technology has advanced enough to cure their fatal illnesses? This is the mission of Tomorrow Biostasis, a Berlin-based startup that specializes in cryopreservation.

Cryopreservation, also known as biostasis or cryonics, is the process of preserving a human body (or brain) in a state of suspended animation, with the hope that it can be revived in the future when medical technology has advanced enough to treat the original cause of death. This may seem like science fiction, but it is a legitimate scientific procedure, and Tomorrow Biostasis is one of the few companies in the world that offers this service.

Dr Emil Kendziorra, co-founder and CEO of Tomorrow Biostasis explained that the goal of cryopreservation is to extend life by preserving the body until a cure can be found for the original illness. He emphasized that cryopreservation is not a form of immortality, but rather a way to give people a second chance at life.

This American cryonics facility has preserved “patients” in liquid nitrogen-filled tanks until a future date when technology allows them to be thawed.

This week our guest is business and technology reporter, Peter Ward. Earlier this year, Peter released his book The Price of Immortality: The Race to Live Forever, where he investigates the many movements and organizations that are seeking to extend human life, from the Church of Perpetual Life in Florida, to some of the biggest tech giants in Silicon Valley.

In this episode, we explore Peter’s findings, which takes us on a tour from cryonics to mind uploading, from supplements to gene editing, and much more. Along the way, we discuss the details of how one might actually achieve immortality, the details of senescent cells and telomeres, whether it’s better to live healthy than to live long, the scams and failures that seem to dominate the space, as well as the efforts that seem most promising.

Continue reading “The Failures and Opportunities of Immortality | Peter Ward, Feedback Loop, ep 75” »

Life is short, but Tomorrow Bio explains how cryonics is a good option that can offer more time for your lifespan. Check out how below!

You can arrange for automatic PayPal payment of Yearly Membership Dues on a Quarterly or Yearly basis AFTER you have filled-in and submitted a membership application and paid the initiation fee which have been received and approved. (You can pay the initiation fee by going to PayPal. From the top menu, select “Personal Send and receive Send Money.” Enter for the email address and make your payment of $75.) Note that when arranging for automatic Quarterly or Yearly payment, the first Quarterly or Yearly payment is made IMMEDIATELY upon arranging for automatic payment.

This is a followup trial result to the first trial that reported 2.5 years of epigenetic age reversal This has interesting reports from the actual patients about how they feel and the changes it made to them. After the first trial I sent an email to see if I could do this but I have IBS which Fahy said would disqualify me.

Dr. Greg Fahy gives an update on the TRIIM-X clinical trial at EARD 2022.

Continue reading “The Thymus As A Key Target For Aging Intervention — Dr. Greg Fahy — EARD 2022” »

2022 https://cryonics.org/wp-content/uploads/2022/11/CI_NEWS-2022-03.pdf.

This issue features:
* President’s Report — New Science Advisory Board.
* 2022 AGM Photos.
* Board of Directors Winners.
* Scale Model CI Cryostats for Sale.
* Cryonics Survey.
* Robert Ettinger’s YOUNIVERSE — Chapter 5
* Latest Cryonics & Life Extension News from Around the Web.

Although my plan is to live forever (or at least, a very long time, societal and natural disasters willing) I know many people in the life-extension community are signed up with a cryonics provider, as a plan B, in case they don’t live long enough to welcome the rejuvenation revolution.

A lot has been written to explain how the people are stored, usually accompanied by a picture of the gleaming liquid nitrogen cooled Dewar flasks, along with the ethical questions of the procedure. However, the journey to the semi-final resting place is often overlooked.

To explore how someone who has signed up to a cryonics program makes that transition, I attended one of the regular cryonics demonstration and training sessions put on by Cryonics UK. It turns out there are 4 key stages in the process – standby, initial cool down, perfusion and transportation.